Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluate the 3-year survival of etanercept in patients over 60 years with psoriasis in moderate / severe plaque and the reasons that led to the abandonment. Besides factors that might have had a positive or negative influence on adherence to treatment and analysis of efficacy (PASI 75) and safety will be identified.
All variables were collected through retrospective review of medical records of patients dermatology unit are made.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| primary ineffectiveness in patients with etanercept treatment | Number of participants not achieve PASI 50 response at 12 weeks | 24 weeks |
| Secondary ineffectiveness in patients with etanercept treatment | Number of participants with Poor adherence to treatment with etanercept", | 24 weeks (duration of treatment with etanercept) |
| Ineffectiveness of treatment in localized lesions in patients with etanercept treatment | Despite having achieved a good response PASI no improvement in critical injuries | 24 weeks(duration of treatment with etanercept) |
| primary ineffectiveness in patients with etanercept treatment | Number of participants not achieve PASI 75 response at 24 weeks | 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with adverse events during treatment with etanercept | 24 weeks | |
| Number of participants with disease remission | 24 weeks | |
| number of participants with Poor adherence to treatment with etanercept |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients over 60 who received etanercept for the treatment of moderate / severe psoriasis
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Enrique Herrera Ceballos, MD | H.U. Virgen de la Victoria | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Clinic | Barcelona | Barcelona | Spain | |||
| H.U. Reina Sofía |
Not provided
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 24 weeks |
| number of participants with Conditions requiring hospitalization and / or surgery | 24 weeks |
| Córdoba |
| Córdoba |
| Spain |
| Hospital de Andújar | Jaén | Jaén | Spain |
| Hospital la Paz | Madrid | Madrid | Spain |
| H.U. Virgen de la Victoria | Málaga | Málaga | Spain |